At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of MK-0873 Following Cumulative Patch and Repeated Max Area Applications in Healthy Subjects and Psoriasis Patients
In Brief
A Phase 1 clinical trial evaluating MK-0873 Patch, MK-0873 Cream, and 3 other interventions for Plaque Psoriasis. Completed, enrolled 42 participants.
Detailed Summary
This study will evaluate the incidence of erythema and other local cutaneous irritation after administration of MK-0873 by patch or cream formulation in healthy participants and participants with mild psoriasis. Part I and Part II in healthy participants will be initiated prior to Part III in psoriasis participants. The primary hypotheses of the study are: 1) that MK-0873 is safe and well tolerated in healthy participants and participants with psoriasis and 2) that the maximum plasma concentration of MK-0873 is \<20 nM in healthy participants and participants with psoriasis.
Study Details
Timeline
Interventions
MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
Plain patch containing no MK-0873 or placebo